Arbutus Biopharma Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABUS research report →
Range $8.5 – $8.5
Price Chart
About the company
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc.
- CEO
- Lindsay Androski
- IPO
- 2007
- Employees
- 19
- HQ
- Warminster, PA, US
Get TickerSpark's AI analysis on ABUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $616.24M
- P/E
- 3.60
- Fwd P/E
- 5.43
- PEG
- 0.00
- P/S
- 3.44
- P/B
- 9.43
- EV/EBITDA
- 1.64
- Div Yield
- 0.00%
- Gross Margin
- 99.99%
- Op Margin
- 79.90%
- Net Margin
- 121.17%
- ROE
- 129.13%
- ROIC
- 147.83%
Latest fiscal year · YoY change
- Revenue
- $14.08M+128.2%
- Gross Profit
- $13.72M+122.3%
- Op Income
- $-27,051,000
- Net Income
- $-33,501,000+52.1%
- EPS
- $-0.17+55.3%
- OCF Growth
- +38.9%
- FCF Growth
- +39.1%
- 52W High
- $5.45
- 52W Low
- $3.50
- 50D MA
- $4.37
- 200D MA
- $4.48
- Beta
- 0.62
- RSI (14)
- 46
- Avg Volume
- 5.22M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arbutus highlighted encouraging HBV program data and said its cash runway extends into Q4 2026, while key next catalysts are AASLD updates on imdusiran and AB-101.· November 6, 2024
- Imdusiran remained the core HBV asset, with management saying the Phase IIa data support advancing it into a Phase IIb trial.
- In IM-PROVE I, the best-performing cohort saw 33% surface antigen loss sustained 24 weeks post-treatment, and 67% in the subgroup with baseline surface antigen below 1,000 IU/mL.
- In IM-PROVE II, imdusiran lowered surface antigen below 100 IU/mL in 95% of patients before VTP-300 or placebo; the company will present preliminary nivolumab-arm data next week.
- AB-101 showed dose-dependent receptor occupancy and generally good tolerability in healthy volunteers, and the study has now moved into HBV patients.
- Cash ended Q3 at approximately $131 million, and management reiterated runway into the fourth quarter of 2026 assuming no financing.
Arbutus ended the third quarter of 2024 with approximately $131 million of cash, cash equivalents and investments in marketable securities, versus approximately $132 million at December 31, 2023. In the first half of 2024, it received approximately $44 million of net proceeds from ATM share issuance and used $54.5 million in operations; no shares were issued under the ATM in Q3. The company still expects 2024 cash burn of $63 million to $67 million, and said cash runway funds operations into Q4 2026, assuming no financing. No revenue or EPS were reported on the call.
Mike McElhaugh framed the quarter around Arbutus’ goal of a functional cure for chronic hepatitis B and emphasized lowering surface antigen first, then adding an immune modulator. He highlighted the company’s view that the data from IM-PROVE I and II support advancing imdusiran as a cornerstone regimen, while AB-101 remains an additional immune-checkpoint approach with potential combination value. His tone was optimistic but measured, repeatedly noting that more data are coming next week at AASLD and that Phase IIb timing is still being worked through with regulators.
David Hastings focused on liquidity and cash usage. He said the company finished Q3 with approximately $131 million in cash, cash equivalents and investments, had $44 million of ATM proceeds in the first half, and used $54.5 million in operations during that period; he also reiterated expected 2024 cash burn of $63 million to $67 million. He added that the runway extends into the fourth quarter of 2026 and later clarified that this runway assumes no financing and does not include expected ATM proceeds.
Analysts pressed management on how to interpret the upcoming functional-cure data, especially the 20% bar and what denominator should be used. Management said 20% is an aspirational threshold, explained the cohort design in IM-PROVE I, and said results should be assessed across the full cohort as well as the subgroup with baseline surface antigen below 1,000 IU/mL. Questions also focused on AB-101 timing and what HBV biomarkers might move; management said the next readout will be HBV patient data in the first half of next year, but it was not yet ready to specify the exact dataset or to promise clear antiviral biomarker effects from a 28-day immune-modulator study. On the legal side, management said the Pfizer/BioNTech Markman hearing is set for December 18, 2024, and the Moderna trial date is now scheduled for September 24, 2025.
The bull case is that Arbutus is showing multiple signs of progress in HBV functional-cure development, including 33% sustained surface antigen loss in the best IM-PROVE I cohort and 95% surface antigen suppression below 100 IU/mL before combination dosing in IM-PROVE II. Management sounded confident that the data support a Phase IIb move for imdusiran, while AB-101 is advancing into HBV patients and the balance sheet appears sufficient into late 2026.
The main risks are that the company still has not presented actual functional-cure outcomes, the next key datasets are pending, and management would not give timing for Phase IIb. AB-101 is still early and management cautioned that a 28-day immune-modulator study may not produce clear hepatitis B efficacy signals, while the legal/IP cases against Moderna and Pfizer/BioNTech remain unresolved and long-dated.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.5%
- Shares Outstanding
- 153.29M
- Float Shares
- 121.79M
of shares held by institutions
182 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 18.38M | ▲ 677.74K |
| Whitefort Capital Management, LP | 15.79M | ▲ 863.38K |
| Blackrock, Inc. | 14.52M | ▲ 749.36K |
| Vanguard Group Inc | 9.24M | ▲ 251.35K |
| Rubric Capital Management LP | 7.53M | ▲ 906.55K |
| State Street Corp | 7.08M | ▼ 787.68K |
| Vanguard Capital Management LLC | 6.99M | ▼ 22.50K |
| Geode Capital Management, LLC | 4.12M | ▲ 3.43K |
| Goldman Sachs Group Inc | 3.51M | ▲ 2.41M |
| Bank Of America Corp | 2.65M | ▲ 962.57K |
| Barclays PLC | 2.55M | ▼ 1.66M |
| Blackbarn Capital Partners LP | 2.50M | 0 |
Held by 230 ETFs
Biggest fund positions in ABUS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Beardsley Robert A | sell | 17,948 |
| Oct 1, 26 | Nguyen Tuan | sell | 48,081 |
| Oct 1, 26 | Sawhney Roger | sell | 17,142 |
| Oct 1, 26 | Androski Lindsay | sell | 24,655 |
| Sep 18, 26 | Androski Lindsay | other | 116,408 |
| Sep 18, 26 | Androski Lindsay | other | 10,456 |
| Sep 18, 26 | Androski Lindsay | other | 116,408 |
| Sep 18, 26 | Androski Lindsay | other | 82,527 |
| Sep 18, 26 | Androski Lindsay | other | 10,456 |
| Sep 18, 26 | Nguyen Tuan | other | 265,625 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABUS coverage
Recent articles, reports, and earnings notes.
No research on ABUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABUS report →Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 10
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
globenewswire.com · Oct 22
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
seekingalpha.com · Oct 8
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened
defenseworld.net · Oct 2
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
globenewswire.com · Oct 1
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
globenewswire.com · Sep 30
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS
defenseworld.net · Sep 1
Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS
defenseworld.net · Aug 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.